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Intestinal Transplantation at the University of Pittsburgh: 
Six-Year Experience 
H. Furukawa, J. Reyes, K. Abu-Elmagd, L. Mieles, W. Hutson, S. Kocoshis, J. Tabasco-Manguillan, 
R.G. Lee, A. Knisley, T.E. Starzl, and S. Todo 
I NfESTINAL transplantation, with tacrolimus-based im-
munosuppression, has become a therapeutic option for 
patients with irreversible intestinal failure. 1- 3 In this report 
we divide the last 6 years of development into three 
chronological phases to assess outcome and to analyze the 
developmental process of intestinal transplantation at the 
University of Pittsburgh. 
MATERIALS AND METHODS 
From May 1990 to August 1996, a total of 86 patients received 
intestinal grafts. either as an isolated graft (SB, n = 33), as a 
combined liver and intestinal graft (SBIL, n = 40), or as a 
composite of multivisceral organs (MV, n = 13). Donor and 
recipient procedures are described elsewhere.4 The major indica-
tions for transplantation in children (n = 52) were gastroschisis 
(n = 13). vulvulus (n = 12), and intestinal atresia (n = 7). and the 
major indications for adults were splanchnic vascular thrombosis 
(n = 9), Crohn's disease (n = 8), and trauma (n = 6). Patients were 
divided into three chronological phases based on immunosuppres-
sive, surgical, and donor/recipient selection strategies. 
Phase 1 (n = 30) spans from May 1990 through October 1992; 
Phase 2 (n = 29) encompasses patients transplanted from Novem-
ber 1992 to December 1994; and Phase 3 includes patients from 
January 1995 to the present. 
Postoperative immunosuppression consisted of tacrolimus, ste-
roids, and prostaglandin El for all phases. Azathioprine, mycophe-
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nolate mofetil, cyclophosphamide, and/or bone marrow transplan-
tation were added as immunosuppressive options in Phase 3. The 
colon was added to the intestinal graft for all patients in Phase 2. 
Donor CMV status was random in Phase 1 and for the first several 
cases of Phase 2, after which strong efforts were made to obtain 
CMV-seronegative donors. Recipient selection was random in 
Phases 1 and 2. In Phase 3, recipients were carefully selected. 
Patient and graft survival rates were determined using Kaplan-
Meier, and the Log-Rank Test was used to compare survival 
curves. A P-value less than .05 was considered significant. 
RESULTS 
Overall actuarial patient and graft survival rates are 73% 
and 60% at 1 year, 58% and 50% at 2 years, and 45% and 
37% at 5 years. Fig 1 shows patient and graft survival rates 
based on phase. One-year patient and graft survival was 
From the Thomas E. Starzl Transplantation Institute, University 
of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 
This work was aided by research grants from the Veterans 
Administration and Project Grant No. DK-29961 from the Na-
tionallnstitutes of Health, Bethesda. Maryland. 
Address reprint requests to H. Furukawa, Thomas E. Starzl 
Transplantation Institute, University of Pittsburgh Medical Cen-
ter, Pittsburgh, PA 15213. 
Graft 
--- Phase 1 ("=31) 
-- Phase 2 (n=32) 
...... Phase 3 (n=281 
2 3 4 5 
Time After Transplantation (years) 
Fig 1. Life table representation 
of clinical intestinal transplanta-
tion patient and graft survival by 
phase of development. 
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86.7% and 80.7% for Phase 1. 58.6% and 43.8(;" for Phase 
2. and 74.4% and 71.5% for Phase 3. Three-year patient 
survival and graft survival rates were 53.3% and 45.2% for 
Phase 1 and 34.5% and 250;, for Phase 2. Phase I graft 
survival was significantly better than Phase 2 graft survival. 
In Phase 1 the major causes of graft loss were rejection (n = 
5), posttransplant lymphoproliferative disease (PTI.D) (n = 
4), and infection (n = 3). In Phase 2 the major causes of 
graft loss were rejection (n = 8), infection (n = 8), and 
PTLD (n = 6). While the ratios of graft loses were similar 
in both phases, CMV -associated graft loss was more prev-
alent in Phase 1 (n = 6) than in Phase 2 (n = 4). Most of the 
infections occurring during Phase 2 were secondary to 
bacteria or fungi, which were presumably related to the 
inclusion of the colon in the graft. Although the follow-up 
is short, most patients in Phase 3 lost their grafts to 
recipient mis-selection, or technical problems. Only two 
patients lost their grafts to rejection. 
So far 13 patients in Phase 3 have received donor-derived 
simultaneous bone marrow transplantation. While I-year 
survival of patients receiving bone marrow transplantation 
(83%) was better than for patients who did not receive bone 
marrow (66%), no statistical difference was seen. 
DISCUSSION 
Our 6-year struggle has highlighted the difficulty and com-
plexity of intestinal transplantation. Although our efforts 
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may have allowed intestinal transplantation to reach a new 
stage of development. further efforts need to be made to 
improve intestinal function and to prevent intestinal rejec-
tion. The colon was added to the intestinal graft in Phase 2 
to try to lessen the problems associated with dysmotility, 
high stomal output, and intractable diarrhea. To overcome 
these recurring problems a trial of clonidine and nifedipine 
was started to try to reduce dysmotility of the intestinal 
grafts. Surgically we are trying to improve intestinal func-
tion by including the intestinal ganglion in the intestinal 
graft. While traditionally the intestinal ganglia were 
stripped from the graft vasculature to ease the anastomosis, 
we currently leave the ganglion intact, hoping to improve 
reinnervation of the graft. Although azathioprine, myco-
phenolate mofetil. and bone marrow transplantation have 
all reduced the incidence of rejection, the development of 
intestinal transplantation requires further improvement of 
immunosuppression or immunomodulation. 
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